Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)
30 de maio de 2017 atualizado por: Otsuka Pharmaceutical Development & Commercialization, Inc.
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease
This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.
Visão geral do estudo
Status
Concluído
Intervenção / Tratamento
Descrição detalhada
This study evaluated whether or not tolvaptan is potentially beneficial, while maintaining an adequate safety profile, by reducing the rate of total kidney volume increase, while impacting the onset, severity, and progression of other important consequences of ADPKD.
During the 3-week titration phase, tolvaptan or placebo was titrated in weekly intervals from lowest to highest tolerated levels given in split-dose regimens of 45/15 mg, 60/30 mg and 90/30 mg orally upon awakening and approximately 9 hours later. As soon as a subject could not tolerate a given dose, the titration phase was over and the maintenance phase began at the dose level tolerated. The maintenance phase lasted to Month 36. Subjects were able to titrate down at any point during the study. Subjects were able to titrate up during the maintenance phase with Medical Monitor approval.
Tipo de estudo
Intervencional
Inscrição (Real)
1445
Estágio
- Fase 3
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Dresden, Alemanha, 1307
- Universitatsklinikum Carl Gustav Carus
-
Düsseldorf, Alemanha, 40210
- Nephrologische Gemeinschaftspraxis/Dialysezentrum
-
Essen, Alemanha, 45147
- Klinik für Nieren- und Hochdruckkrankheiten
-
Freiburg, Alemanha, 78106
- Universitatsklinikum Freiburg
-
Heidelberg, Alemanha, 69120
- Universitätskliniken Heidelberg
-
Nuernberg, Alemanha, 90471
- UH Erlangen/Nürnberg
-
-
-
-
-
Buenos Aires, Argentina, 1425
- Instituto de Nefrología, Nefrology SA
-
Buenos Aires, Argentina, 1602
- Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay
-
Buenos Aires, Argentina, B1664INZ
- Hosptial Universitario Austral
-
Cordoba, Argentina, X5000IUP
- Sanatorio Allende
-
Cordoba, Argentina, X5016KEA
- Hospital Privado-Centro Medico de Cordoba
-
-
-
-
-
Adelaide, Austrália, 5000
- Royal Adelaide Hospital
-
Adelaide, Austrália, 5011
- Queen Elizebeth Hospital
-
Brisbane, Austrália, 4102
- Princess Alexandra Hospital
-
Melbourne, Austrália, 3050
- Royal Melbourne Hospital
-
Melbourne, Austrália, 3121
- Melbourne Renal Research Group
-
Perth, Austrália, 6054
- Royal Perth Hospital
-
Sydney, Austrália, 2065
- Royal North Shore Hospital
-
Sydney, Austrália, 2145
- Westmead Hospital
-
-
-
-
-
Brussel, Bélgica, 1090
- UZ Brussel
-
Brussels, Bélgica, 1200
- UCL-St Luc
-
Gent, Bélgica, 9000
- UZ Gent
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H1v8
- Queen Elizabeth II Health Science Center, Division of Nephrology
-
-
Quebec
-
Montreal, Quebec, Canadá, H3A1A1
- Royal Victoria Hospital
-
Montreal, Quebec, Canadá, H4J1C5
- Hospital du Sacre- Coeur de Montreal
-
-
-
-
-
Herlev, Dinamarca, 2730
- Herlev Amtssygehus
-
Odense, Dinamarca, 5000
- Odense Universitetshospital
-
-
-
-
Alabama
-
Mobile, Alabama, Estados Unidos, 36617
- University of South Alabama
-
Mobile, Alabama, Estados Unidos, 36608
- Coastal Clinical Research
-
-
California
-
Riverside, California, Estados Unidos, 92503
- Apex Research of Riverside
-
Stanford, California, Estados Unidos, 94305-5114
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80262
- University of Colorado Health Sciences Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Yale University School Of Medicine
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32216
- Jacksonville Center for Clinical Research
-
Port Charlotte, Florida, Estados Unidos, 33952
- Coastal Nephrology Associates Research Center, LLC
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Renal Associates of Baton Rough, L.L.C.
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts- New England Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Medical Center
-
-
New York
-
Buffalo, New York, Estados Unidos, 14215
- Erie County Medical Center
-
Hawthorne, New York, Estados Unidos, 10532
- Nephrology Associates of Westchester
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10021
- The Rogosin Institute
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- University of North Carolina, UNC, Kidney Center
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220
- Kidney and Hypertension Center
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals of Cleveland/Case
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97210
- Northwest Renal Clinic, Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29405
- Charleston Nephrology Associates
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37205
- Nephrology Associates, P.C.
-
Nashville, Tennessee, Estados Unidos, 37232-1371
- Vanderbilt University Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia, Nephrology Clinical Research Center
-
-
-
-
-
Kemerovo, Federação Russa, 650061
- Kemerovo Medical Academy, Regional Clinical Hospital
-
Moscow, Federação Russa, 123060
- City Clinical Hospital #52
-
St. Petersburg, Federação Russa, 191104
- City Mariinskiy Hospital
-
St.-Petersburg, Federação Russa, 194291
- Leningrad Regional Clinical Hospital
-
Tomsk, Federação Russa, 634063
- Tomsk Regional Clinical Hospital
-
-
-
-
-
Bordeaux, França, 33076
- CHU-Hopital Pellegrin
-
Caen Cedex, França, 14033
- CHU - Hôpital Clémenceau
-
Lyon Cedex 3, França, 69437
- Hôpital Edouard Herriot
-
Marseille, França, 13005
- Hopital de la Conception
-
Montpellier, França, 34295
- CHU - Hôpital Lapeyronie
-
Paris, França, 75018
- Hôpital Bichat-Claude Bernard
-
Reims cedex, França, 51092
- Centre Hospitalier Universitaire
-
Saint-Etienne Cedex 2, França, 42055
- Chu - Hopital Nord
-
Toulouse Cedex 09, França, 31059
- Hopital Rangueil
-
-
-
-
-
Amsterdam, Holanda, 1081 HV
- VU Medisch Centrum
-
Groningen, Holanda, 9713 GZ
- UMCG Groningen
-
-
-
-
-
Bergamo, Itália, 24128
- Ospedali Riuniti di Bergamo
-
Milano, Itália, 20132
- Università Vita e Salute, Ospedale San Raffaele
-
Modena, Itália, 41100
- Policlinico di Modena
-
Napoli, Itália, 80131
- Policlinico
-
Pavia, Itália, 27100
- IRCCS Fondazione Salvatore Maugeri
-
-
-
-
-
Chiba, Japão, 2608677
- Chiba University Hospital
-
Chiba, Japão, 2608712
- National Hospital Organization Chiba-East Hospital
-
Fukuoka, Japão, 8128582
- Kyusyu University Hospital
-
Fukushima, Japão, 9601295
- Fukushima Medical University Hospital
-
Hiroshima, Japão, 7348551
- Hiroshima University Hospital
-
Kumamoto, Japão, 8608556
- Kumamoto Univeristy Hospital
-
Kyoto, Japão, 6068507
- Kyoto University Hospital
-
Kyoto, Japão, 612-8555
- National Hospital Organization Kyoto Medical Center
-
Niigata, Japão, 9518520
- Niigata University Medical & Dental Hospital
-
Osaka, Japão, 5500015
- Ohno Memorial Hospital
-
Saitama, Japão, 3308503
- Saitama Medical Center Jichi Medical University
-
-
Aichi
-
Toyoake, Aichi, Japão, 4701192
- Fujita Health University Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 608648
- Hokkaido University Hospital
-
-
Kanagawa
-
Isehara, Kanagawa, Japão, 2591193
- Tokai University Hospital
-
Kawasaki, Kanagawa, Japão, 2138587
- Toranomon Hospital Kajigaya
-
Sagamihara, Kanagawa, Japão, 2288555
- Kitasato University Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japão, 9808574
- Tohoku University Hospital
-
-
Osaka
-
Osaka-City, Osaka, Japão, 5458586
- Osaka City University Hospital
-
Suita, Osaka, Japão, 5650871
- Osaka University Hospital
-
-
Saitama
-
Kasukabe, Saitama, Japão, 3440035
- Shuwa General Hospital
-
Kawagoe, Saitama, Japão, 3508500
- Saitama Medical Center
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japão, 4313192
- Hamamatsu University School of Medicine, University Hospital
-
-
Tochigi
-
Shimotsuke, Tochigi, Japão, 3290498
- Jichi Medical School Hospital
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japão, 1138603
- Nippon Medical School Hospital
-
Bunkyo-ku, Tokyo, Japão, 1138519
- Tokyo Medical & Dental University Hospital, Faculty of Medicine
-
Itabashi-ku, Tokyo, Japão, 1738606
- Teikyo University Hospital
-
Minato-Ku, Tokyo, Japão, 1058471
- The Jikei University Hospital
-
Minato-ku, Tokyo, Japão, 1058470
- Toranomon Hospital
-
Mitaka, Tokyo, Japão, 1818611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo, Japão, 1628666
- Tokyo Women's Medical University Hospital
-
-
-
-
-
Ciechanow, Polônia, 06-400
- Oddział Nefrologiczny Stacja Dializ
-
Gdansk, Polônia, 80-952
- Akademickie Centrum Kliniczne AMG
-
Gdansk, Polônia, 80-952
- Samodzielny Publiczny Szpital Kliniczny nr 1, Akademickie Centrum Kliniczne AMG
-
Krakow, Polônia, 31-501
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Szpital Uniwersytecki w Krakowie
-
Lodz, Polônia, 90-153
- SOP ZOZ Uniwersytecki Szpital Kliniczny
-
Lublin, Polônia, 20-954
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
-
Warsaw, Polônia, 04-749
- Międzyleski Szpital Specjalistyczny w Warszawie
-
Warsaw, Polônia, 02-507
- Klinika Chorób Wewnętrznych i Nefrologii
-
Warszawa, Polônia, 03-401
- Szpital Praski p.w. Przemienienia Panskiego, Samodzielny Publiczny Zaklad Opieki Zdrowotnej
-
Warszawa, Polônia, 03-401
- Szpital Praski, Samodzielny Publiczny ZOZ
-
Wroclaw, Polônia, 50-417
- Akademicki Szpital Kliniczny im J Mikulicza Radeckiego
-
-
-
-
-
Belfast, Reino Unido, BT9 7AB
- Belfast City Hospital
-
Birmingham, Reino Unido, B15 2TH
- Oueen Elizabeth Hospital
-
Brighton, Reino Unido, BN2 5BE
- Sussex Renal Unit Royal Sussex County Hospital
-
Coventry, Reino Unido, CV2 2DX
- Uhcw Mhs Trust
-
Edinburgh, Reino Unido, EH16 4SA
- Royal Infirmary
-
Inverness, Reino Unido, IV2 3UJ
- Raigmore Hospital
-
London, Reino Unido, NW3 2PF
- Royal Free and University College Medical School
-
London, Reino Unido, SE5-9RS
- King's College Hospital
-
London, Reino Unido, SW170RE
- St. George's Hospital
-
Sheffield, Reino Unido, S5 7AU
- Royal Hallamshire Hospital
-
Swansea, Reino Unido, SA6 6NL
- Morriston Hospital
-
-
-
-
-
Bucharest, Romênia, 22328
- Institutul Clinic Fundeni
-
Bucharest, Romênia, 10731
- Spitalul Clinic de Nefrologie Dr. Carol Davila
-
Iasi, Romênia, 700503
- Spitalul Clinic "C.I.Parhon"
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 50 anos (Adulto)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Legal adult age and able to give Informed Consent.
- Adult subjects with a diagnosis of ADPKD. A diagnosis of ADPKD (age 18 or 20-50) required several cysts in each kidney (3 if by sonography, 5 if by CT or MRI) in those with a family history of ADPKD and 10 cysts (by any radiologic method) in each kidney and exclusion of other cystic kidney diseases if there was no family history.
- Willingness to comply with reproductive precautions, if female.
- Estimated creatinine clearance ≥ 60 mL/min. Estimated from serum creatinine during screening using Cockcroft-Gault with correction for gender and race, where possible.
- Rapidly progressive kidney growth (total volume ≥ 750 cc) by magnetic resonance imaging (MRI) at randomization.
Exclusion Criteria:
- Prior exposure to tolvaptan or other experimental PKD therapies.
- Currently taking medication for purpose of affecting PKD cysts.
- Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods.
- In the opinion of the study investigator or sponsor may present a safety risk or confound study objectives.
- Patients who are unlikely to adequately comply with study procedures.
- Patients having contraindications to MRI.
- Patients taking medications or having any illnesses likely to affect ADPKD outcomes.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Tolvaptan
Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
|
Tolvaptan was supplied as tablets.
Outros nomes:
|
|
Comparador de Placebo: Placebo
Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
|
Placebo was supplied as tablets.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36
Prazo: Baseline to Month 36
|
Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility.
At the central reviewing facility, blinded radiologists used proprietary software to measure the volume of both kidneys.
|
Baseline to Month 36
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36
Prazo: Baseline to Month 36
|
These ADPKD events in the key secondary Outcome Measure were selected on the basis of their potential relationship to progressing cystogenesis.
Reducing the rate of cyst development and expansion would likely slow the progression of ADPKD.
The 4 events were: (1) Onset or progression of hypertension (someone is hypertensive if they have > 139 mmHg systolic blood pressure [BP], > 89 mmHg diastolic BP, or if they are taking antihypertensive medication at any BP level); (2) severe renal pain requiring medical intervention; (3) worsening albuminuria (by category, see below); and (4) worsening renal function, defined as a 25% decrease in 1/serum creatinine from Baseline.
Albuminuria was assessed using spot urine albumin/creatinine ratio measurements (all measurements in mg/mmol).
Categories included normal (< 2.8 female or < 2.0 male), microalbuminuria (2.8-28 female or 2.0-20 male), and overt proteinuria (> 28 female or > 20 male.
|
Baseline to Month 36
|
|
Change in Renal Function Per Year From Week 3 to Month 36
Prazo: Week 3 to Month 36
|
Renal function was assessed using serum creatinine measurements and was estimated using 1/serum creatinine.
The formula for 1/serum creatinine is: 1/Pcr, where Pcr = serum creatinine concentration (mg/dL).
The change in renal function per year was based on the slope of change, obtained by regressing renal function data against time by subject.
|
Week 3 to Month 36
|
|
Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36
Prazo: Baseline to Month 36
|
For participants who were non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) at baseline, mean arterial blood pressure was measured at scheduled clinic visits up to the point of exposure to antihypertensive therapy for any reason.
The change in mean arterial blood pressure per year was based on the slope of blood pressure, obtained by regressing blood pressure against time by subject.
|
Baseline to Month 36
|
|
Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36
Prazo: At screening, Baseline, Day 1, every 4 months up to month 36/early tremination (ET), follow-up visit 1 and 2
|
Change from baseline in renal pain was assessed by a 0 to 10 pain scale as average area under the concentration-time curve (AUC) between baseline and the last trial visit or the last visit prior to initiating medical (eg, narcotic or anti-nociceptives [eg, tricyclic antidepressants]) or surgical therapy for pain.
In the pain scale, score 0 represented no pain at all and score 10 represented the worst pain.
A negative change score indicates less pain.
AUC of renal pain was derived from renal pain scores within treatment period and was calculated using the trapezoidal rule, by dividing the number of days between the first and last assessment.
|
At screening, Baseline, Day 1, every 4 months up to month 36/early tremination (ET), follow-up visit 1 and 2
|
|
Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36
Prazo: Baseline to Month 36
|
A hypertensive event was defined as a change from non-hypertensive (systolic BP ≤ 139 mmHg and diastolic BP ≤ 89 mmHg without taking antihypertensive medications) status to 1 of 3 conditions: (1) High pre-hypertensive (systolic BP [sBP] > 129 mmHg and/or diastolic BP [dBP] > 84 mmHg), (2) hypertensive (sBP > 139 mmHg and/or dBP > 89 mmHg), or (3) requiring antihypertensive therapy.
|
Baseline to Month 36
|
|
Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36
Prazo: Baseline to Month 36
|
Baseline to Month 36
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Colaboradores
Investigadores
- Investigador principal: Vicente Torres, MD, PhD, Mayo Medical Center
- Diretor de estudo: Frank Czerwiec, MD, PhD, Otsuka Pharmaceutical Development and Commercialization, Inc.
- Diretor de estudo: Osamu Sato, Otsuka Pharmaceutical Corporation, Ltd. Japan
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Publicações Gerais
- Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
- Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.
- Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323-6. doi: 10.1038/nm935. Epub 2003 Sep 21.
- Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004 Apr;10(4):363-4. doi: 10.1038/nm1004. Epub 2004 Feb 29.
- Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf. 2015 Nov;38(11):1103-13. doi: 10.1007/s40264-015-0327-3.
- Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.
- Kher A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1257-8. doi: 10.1056/NEJMc1300762. No abstract available.
- Spital A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1257. doi: 10.1056/NEJMc1300762. No abstract available.
- Torres VE, Gansevoort RT, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1259. doi: 10.1056/NEJMc1300762. No abstract available.
- Jouret F, Krzesinski JM. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1258-9. doi: 10.1056/NEJMc1300762. No abstract available.
- Sexton DJ. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013 Mar 28;368(13):1258. doi: 10.1056/NEJMc1300762. No abstract available.
- Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. doi: 10.2215/CJN.16871020. Epub 2021 Jun 11.
- Heida JE, Gansevoort RT, Torres VE, Devuyst O, Perrone RD, Lee J, Li H, Ouyang J, Chapman AB. The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. J Am Soc Nephrol. 2021 Jul;32(7):1801-1812. doi: 10.1681/ASN.2020101512. Epub 2021 Apr 22.
- McEwan P, Bennett Wilton H, Ong ACM, Orskov B, Sandford R, Scolari F, Cabrera MV, Walz G, O'Reilly K, Robinson P. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol. 2018 Feb 13;19(1):37. doi: 10.1186/s12882-017-0804-2.
- Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.
- Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, Ouyang J, Torres VE, Horie S. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015 Oct;19(5):867-77. doi: 10.1007/s10157-015-1086-2. Epub 2015 Feb 7.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de janeiro de 2007
Conclusão Primária (Real)
1 de janeiro de 2012
Conclusão do estudo (Real)
1 de janeiro de 2012
Datas de inscrição no estudo
Enviado pela primeira vez
26 de janeiro de 2007
Enviado pela primeira vez que atendeu aos critérios de CQ
29 de janeiro de 2007
Primeira postagem (Estimativa)
30 de janeiro de 2007
Atualizações de registro de estudo
Última Atualização Postada (Real)
2 de julho de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
30 de maio de 2017
Última verificação
1 de maio de 2017
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Urológicas
- Anomalias congénitas
- Doenças Genéticas, Congênitas
- Doenças articulares
- Doenças musculoesqueléticas
- Doenças Musculares
- Anormalidades musculoesqueléticas
- Anormalidades, Múltiplas
- Doenças Renais Císticas
- Ciliopatias
- Doenças renais
- Doenças Renais Policísticas
- Rim Policístico, Autossômico Dominante
- Artrogripose
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Natriuréticos
- Antagonistas dos receptores do hormônio antidiurético
- Tolvaptano
Outros números de identificação do estudo
- 156-04-251
- 2006-002768-24 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .